PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Marco Stellato

Fondazione IRCCS Istituto Nazionale dei Tumori

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs1 Trials Reviews1 Guidelines

Latest

Everything in the corpus, newest first.

AUG 7, 2026 · REVIEW

Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis

Targeted Oncology

Reconstructed IPD meta-analysis of 1638 patients shows PSA nadir ≤0.2 associated with substantial OS and PFS improvements (HR 0.27 and 0.19 respectively, both p<0.0001), providing robust evidence for PSA nadir as a prognostic marker in mHSPC.

Strong EvidenceProstate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Marco Stellato

Reported

Sample size (OS analysis)1638

Sample size (PFS analysis)1104

Median PFS nadir ≤0.2not reached

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support